The Story
News Summary
- Amgen (AMGN) continues its strong uptrend, outperforming biotech benchmarks with 32.1% YTD gains following robust Q2 earnings beats.
- Trading near 52-week highs above key moving averages, the mega-cap drugmaker leverages solid revenue, free cash flow, and expanding pipeline assets to drive sustained market leadership.
Explore US30 price history & advisor snapshot
These are separate market snapshots and may predate this story. Check the data period, generation time and expiry before using them in your research.
Stored market data
US30 price history
51778.04
+9.49% over the displayed period
Advisor Snapshot
Unlock Member-Only Insights
Reserved for TradingNews24 members. Log in or create a free account to access market signals and exclusive tools.